Member Info for crumbs

I hate golf :)

If there was a leak to do with hmm BioNtech... you might think someone who may be a Mainz local might want some off the Boerse...a place that is usually one emptiness of no trades for years on end... ohhh wait!
Anyways no point in speculating if it is to be there will be an RNS

We should at least thank him for retaining moditope as part of scancell... now Lindy has even brought in more of her tech with the glycan MABs tech... poundland BioNtech ;)

I've come to the conclusion the likelihood is it is DE... I would not say he has said anything outrageous or negative beyond they could not nab a SCIB1 deal during his time at scancell which is a well know fact due to there being no SCIB1 deal lol... his memory of events by his own admittance is not so clear either...The company has come on a great amount since his departure despite our current sp ... he needed to go when he went and funny how the ones who were all calling for his head are now trying to be his bessie mates over there lol....

Doing a presentation in Germany today titled:

13:18–13:42
Individualized cancer immunotherapy: Beyond targeting neoantigens
Ugur Sahin (Mainz)

No more details... so who knows what that is all about but no doubt interesting ....

In the oven

'Gilead takes an $820M hit after axing a Kite CAR-T. Are billions more going to be incinerated?'

https://endpts.com/gilead-takes-an-820m-hit-after-axing-a-kite-car-t-are-billions-more-going-to-be-incinerated/

'Gets serious'

GlaxoSmithKline is showing its determination to make up for lost time in oncology by signing a major new immunotherapy partnership with Germany’s Merck.

The two companies have just unveiled a global alliance to jointly develop and commercialise M7824, a novel immunotherapy with potential in a number of difficult-to-treat cancers, which could be worth a very sizeable $4.2bn (€3.7 billion or £3.2bn) to the Darmstadt-headquartered firm.

http://www.pmlive.com/pharma_news/gsk_gets_serious_about_immunotherapy_with_merck_deal_worth_up_to_$4.2bn_1277435

My quote was from the exact same RNS... if you email scancell they may be able to address your worries about the process...

It is called Ichor TriGrid v2 a commercial version of the original device that was developed with money from Pfizer...and is already in use in a trial in Europe used by J&J,

'scancell exercised its option to a worldwide commercial licence for the use of Ichor Medical Systems' TriGrid® 2.0 electroporation delivery system with SCIB1

This enables Scancell to use TriGrid® 2.0 as the delivery system for its planned Phase 2 checkpoint inhibitor combination study with SCIB1'

That is good news indeed about Tom... And I wonder will Southampton play a part in both scancells upcoming trials.... you would think so.

Anyways Evans might be about to regret his retirement hobby lol

Ray as a mono SCIB1 was and is only statistically more effective than alternatives in early stage and resected... It was rather amazing it showed tumour shrinkage in lungs... you do not see that with such vaccines.. only in ones where the tumour is directly injected... what is most impressive with our date is the longevity of benefit... that's the difference
we do need that combo trial though to get the full SCIB1 picture

No no its like United... Fergie is pulling Ollies strings... DE is behind it all too lol

So a very good chance of a deal with BioNtech and Genentech in the wings... don't think we had that 3 years ago!...

That he thinks there is more with Genentech though isnt it... he would know after all.. with his history :)

https://www.calculuscapital.com/cms/media/Scancell-Cap-mkts_all.pdf

page 69...

Not really sure what new he is saying?....He and RG failed to get a deal on SCIB1.... errr I think we all know that :)....
maybe that is why we now have 2 platforms multiple products and glycan MABs to boot... not just hanging onto SCIB1.... RG did go on to manage to pull of a SCIB2 deal all be it not an upfront commercial one...

https://www.researchgate.net/publication/323217427_Targeting_gp100_and_TRP-2_with_a_DNA_vaccine_Incorporating_T_cell_epitopes_with_a_human_IgG1_antibody_induces_potent_T_cell_responses_that_are_associated_with_favourable_clinical_outcome_in_a_phase_II

A history of when we did not have an exceptional number of SCIB1 trial patients exceeding 5 years survival... stimulating the interests of Keith Flaherty and other top US clinicians who will now run SCIB1 combo trial
A history where SCIB2 did not get CRUK validation and a free development and trials ride from them to potential commercialisation
plus moving away from Ichor.

A history of no moei1/Amplivant... no modi2... no 'new TCR theraputics' backed by a collaboration with BioNtech (the immuno powerhouse of Europe)

We all love a bit of history and should indeed learn from it... but scancell is not stuck in the past